1.3M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 850,000 | 850,000 (5%) | 5% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 2,250,000 | 3,337,386 (20%) | 13% | 0 | Common Stock | |
| Christophe Arbet-Engels | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 850,000 | 864,207 (5%) | 5% | 0 | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 650,000 | 1,140,980 (7%) | 4% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 74,773 | 74,773 (0%) | 0% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.45 per share. | 23 Jan 2025 | 74,773 | 0 (0%) | 0% | 0.5 | 33,947 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.45 per share. | 23 Jan 2025 | 76,473 | 1,087,386 (6%) | 0% | 0.5 | 34,719 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 169,940 | 1,163,859 (7%) | 1% | 0 | Common Stock | |
| Christophe Arbet-Engels | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 25,831 | 25,831 (0%) | 0% | 0 | Common Stock | |
| Christophe Arbet-Engels | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.45 per share. | 23 Jan 2025 | 11,624 | 14,207 (0%) | 0% | 0.5 | 5,284 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 61,178 | 513,238 (3%) | 0% | 0 | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.45 per share. | 23 Jan 2025 | 22,258 | 490,980 (3%) | 0% | 0.5 | 10,094 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.39 per share. | 15 Nov 2024 | 31,897 | 993,919 (6%) | 0% | 0.4 | 12,583 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 15 Oct 2024 | 31,897 | 1,025,816 (6%) | 0% | 0.6 | 17,926 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 230,645 | 230,645 (1%) | 1% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 04 Oct 2024 | 230,645 | 0 (0%) | 1% | 0.6 | 126,901 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 532,081 | 1,297,149 (8%) | 3% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 04 Oct 2024 | 239,436 | 1,057,713 (6%) | 1% | 0.5 | 131,522 | Common Stock |
| Arthur Taveras | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 230,645 | 464,946 (2%) | 1% | 0 | Common Stock | |
| Arthur Taveras | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 04 Oct 2024 | 76,920 | 388,026 (2%) | 0% | 0.6 | 43,306 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.57 per share. | 04 Oct 2024 | 67,695 | 452,060 (2%) | 0% | 0.6 | 38,329 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 230,645 | 519,755 (3%) | 1% | 0 | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 09 Sep 2024 | 2,642 | 289,110 (1%) | 0% | 0.7 | 1,738 | Common Stock |
| David W.J. McGirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 96,667 (0%) | 0% | 0 | Common Stock | |
| Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 121,667 (0%) | 0% | 0 | Common Stock | |
| William E. Aliski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 96,667 (0%) | 0% | 0 | Common Stock | |
| Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 96,667 (0%) | 0% | 0 | Common Stock | |
| Gary J. Bridger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 96,667 (0%) | 0% | 0 | Common Stock | |
| Murray W. Stewart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 191,504 (1%) | 0% | 0 | Common Stock | |
| Robert Keith Woods | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 135,000 (0%) | 0% | 0 | Common Stock | |
| Francoise de Craecker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 45,000 | 96,667 (0%) | 0% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 11 Mar 2024 | 52,500 | 0 (0%) | 0% | 0.9 | 46,347 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 11 Mar 2024 | 49,678 | 765,068 (4%) | 0% | 0.9 | 43,856 | Common Stock |
| Arthur Taveras | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 11 Mar 2024 | 14,235 | 234,301 (1%) | 0% | 0.9 | 12,552 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 11 Mar 2024 | 15,409 | 291,752 (1%) | 0% | 0.9 | 13,591 | Common Stock |
| Taveras Arthur | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 428,248 | 428,248 | - | - | Stock Appreciation Right | |
| Paula Ragan S. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 1,189,578 | 1,189,578 | - | - | Stock Appreciation Right | |
| Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 428,248 | 428,248 | - | - | Stock Appreciation Right | |
| Mostafa S. Adam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 523,414 | 523,414 | - | - | Stock Appreciation Right | |
| Christophe Arbet-Engels | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 180,816 | 180,816 | - | - | Stock Appreciation Right | |
| DiBiase Mary | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 12 Feb 2024 | 3,683 | 307,161 (1%) | 0% | 1.0 | 3,709 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 12 Feb 2024 | 21,695 | 814,746 (5%) | 0% | 1.0 | 21,892 | Common Stock |
| Mostafa S. Adam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 12 Feb 2024 | 27,721 | 52,500 (0%) | 0% | 1.0 | 27,973 | Common Stock |
| Arthur Taveras | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 12 Feb 2024 | 787 | 248,536 (1%) | 0% | 1.0 | 793 | Common Stock |
| Michael Stephen Wyzga | Director | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 18 Aug 2023 | 25,000 | 76,667 (0%) | 0% | 1.2 | 29,875 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.89 per share. | 30 Jun 2023 | 2,641 | 80,221 (0%) | 0% | 1.9 | 4,991 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.89 per share. | 30 Jun 2023 | 464 | 150,536 (0%) | 0% | 1.9 | 877 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 23 Jun 2023 | 5,417 | 82,862 (0%) | 0% | 1.9 | 10,455 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.92 per share. | 23 Jun 2023 | 6,724 | 543,797 (3%) | 0% | 1.9 | 12,910 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 1.93 per share. | 23 Jun 2023 | 857 | 151,000 (0%) | 0% | 1.9 | 1,654 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.22 per share. | 15 Jun 2023 | 5,417 | 88,279 (0%) | 0% | 2.2 | 12,026 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.23 per share. | 15 Jun 2023 | 6,724 | 550,521 (3%) | 0% | 2.2 | 14,995 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 2.23 per share. | 15 Jun 2023 | 857 | 151,857 (0%) | 0% | 2.2 | 1,911 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.95 per share. | 31 May 2023 | 6,292 | 557,245 (3%) | 0% | 1.9 | 12,269 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 10 Mar 2023 | 52,500 | 93,696 (0%) | 0% | 0.8 | 44,100 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 10 Mar 2023 | 49,678 | 563,537 (3%) | 0% | 0.8 | 41,730 | Common Stock |
| Arthur Taveras | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 10 Mar 2023 | 16,806 | 86,373 (0%) | 0% | 0.8 | 14,117 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 10 Mar 2023 | 18,192 | 152,714 (0%) | 0% | 0.8 | 15,281 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.93 per share. | 13 Feb 2023 | 27,721 | 146,196 (0%) | 0% | 0.9 | 25,781 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.93 per share. | 13 Feb 2023 | 21,695 | 613,215 (3%) | 0% | 0.9 | 20,176 | Common Stock |
| Arthur Taveras | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 0.93 per share. | 13 Feb 2023 | 928 | 103,179 (0%) | 0% | 0.9 | 863 | Common Stock |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.93 per share. | 13 Feb 2023 | 4,348 | 170,906 (1%) | 0% | 0.9 | 4,044 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2022 | 1,350,000 | 1,350,000 | - | - | Stock Appreciation Right | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2022 | 3,438,335 | 3,438,335 | - | - | Stock Appreciation Right | |
| Arthur Taveras | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2022 | 1,000,000 | 1,000,000 | - | - | Stock Appreciation Right | |
| Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2022 | 1,350,000 | 1,350,000 | - | - | Stock Appreciation Right | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 17 Aug 2022 | 10,834 | 173,917 (1%) | 0% | - | Common Stock | |
| Derek M. Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 17 Aug 2022 | 8,334 | 145,155 (0%) | 0% | - | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 17 Aug 2022 | 13,448 | 634,910 (3%) | 0% | - | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 17 Aug 2022 | 1,713 | 177,896 (1%) | 0% | - | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 30 Jun 2022 | 2,641 | 184,751 (1%) | 0% | - | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 30 Jun 2022 | 1,578 | 179,609 (1%) | 0% | - | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 24 Jun 2022 | 5,416 | 187,392 (1%) | 0% | - | Common Stock | |
| Derek M. Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 24 Jun 2022 | 4,166 | 153,489 (0%) | 0% | - | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 24 Jun 2022 | 6,724 | 648,358 (4%) | 0% | - | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 24 Jun 2022 | 856 | 181,187 (1%) | 0% | - | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jun 2022 | 5,416 | 192,808 (1%) | 0% | - | Common Stock | |
| Derek M. Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jun 2022 | 4,166 | 157,655 (0%) | 0% | - | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jun 2022 | 6,724 | 655,082 (4%) | 0% | - | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 16 Jun 2022 | 856 | 182,043 (1%) | 0% | - | Common Stock | |
| David W.J. McGirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | |
| Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | |
| William E. Aliski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | |
| Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | |
| Gary J. Bridger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | |
| Murray W. Stewart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | |
| Francoise de Craecker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 6,667 | 6,667 (0%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.21 per share. | 03 Jun 2022 | 6,292 | 661,806 (4%) | 0% | 1.2 | 7,613 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 105,000 | 198,224 (1%) | 0% | 0 | Common Stock | |
| Derek M. Meisner | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 105,000 | 161,821 (1%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 220,789 | 668,098 (4%) | 1% | 0 | Common Stock | |
| Diego Cadavid | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 97,000 | 104,107 (0%) | 0% | 0 | Common Stock | |
| Arthur Taveras | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 97,000 | 104,107 (0%) | 0% | 0 | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 105,000 | 182,899 (1%) | 0% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 Feb 2022 | 27,721 | 93,224 (0%) | 0% | - | Common Stock | |
| Derek M. Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 Feb 2022 | 15,909 | 56,821 (0%) | 0% | - | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 Feb 2022 | 21,695 | 447,309 (2%) | 0% | - | Common Stock | |
| Diego Cadavid | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 Feb 2022 | 928 | 7,107 (0%) | 0% | - | Common Stock | |
| Arthur Taveras | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 11 Feb 2022 | 928 | 7,107 (0%) | 0% | 0 | Common Stock | |
| Mary DiBiase | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 11 Feb 2022 | 12,545 | 77,899 (0%) | 0% | - | Common Stock | |
| Francoise de Craecker | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2021 | 12,250 | 12,250 | - | - | Stock Option (right to buy) | |
| Mary DiBiase | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2021 | 27,000 | 90,444 (0%) | 0% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.10 per share. | 17 Aug 2021 | 10,832 | 120,945 (0%) | 0% | 5.1 | 55,243 | Common Stock |
| Derek M. Meisner | General Counsel | Sale of securities on an exchange or to another person at price $ 5.10 per share. | 17 Aug 2021 | 8,332 | 72,730 (0%) | 0% | 5.1 | 42,493 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 5.10 per share. | 17 Aug 2021 | 13,448 | 469,004 (2%) | 0% | 5.1 | 68,585 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 5.78 per share. | 15 Jul 2021 | 13,448 | 482,452 (2%) | 0% | 5.8 | 77,729 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.64 per share. | 30 Jun 2021 | 2,641 | 131,777 (0%) | 0% | 6.6 | 17,536 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.01 per share. | 23 Jun 2021 | 5,417 | 134,418 (0%) | 0% | 7.0 | 37,973 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 16,250 | 139,835 (0%) | 0% | 0 | Common Stock | |
| Derek M. Meisner | General Counsel | Sale of securities on an exchange or to another person at price $ 7.00 per share. | 23 Jun 2021 | 4,166 | 81,062 (0%) | 0% | 7 | 29,162 | Common Stock |
| Derek M. Meisner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 12,500 | 85,228 (0%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 44,826 | 495,900 (3%) | 0% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 16,250 | 129,002 (0%) | 0% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.84 per share. | 15 Jun 2021 | 5,417 | 123,585 (0%) | 0% | 7.8 | 42,469 | Common Stock |
| Derek M. Meisner | General Counsel | Sale of securities on an exchange or to another person at price $ 7.84 per share. | 15 Jun 2021 | 4,166 | 72,728 (0%) | 0% | 7.8 | 32,661 | Common Stock |
| Derek M. Meisner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 12,500 | 76,894 (0%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 44,826 | 451,074 (2%) | 0% | 0 | Common Stock | |
| David W.J. McGirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| William E. Aliski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Gary J. Bridger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Murray W. Stewart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.50 per share. | 02 Jun 2021 | 2,400 | 406,248 (2%) | 0% | 9.5 | 22,800 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.41 per share. | 01 Jun 2021 | 4,104 | 408,648 (2%) | 0% | 9.4 | 38,619 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.33 per share. | 03 May 2021 | 2,400 | 412,752 (2%) | 0% | 8.3 | 19,992 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.17 per share. | 05 Apr 2021 | 2,400 | 415,152 (2%) | 0% | 9.2 | 22,008 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 83,163 | 112,752 (0%) | 0% | 0 | Common Stock | |
| Derek M. Meisner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 47,728 | 64,394 (0%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 144,629 | 417,552 (2%) | 0% | 0 | Common Stock | |
| Diego Cadavid | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 8,035 | 8,035 (0%) | 0% | 0 | Common Stock | |
| Arthur Taveras | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2021 | 8,035 | 8,035 (0%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.74 per share. | 02 Mar 2021 | 2,400 | 272,923 (1%) | 0% | 9.7 | 23,376 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.88 per share. | 02 Feb 2021 | 2,400 | 275,323 (1%) | 0% | 7.9 | 18,912 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.00 per share. | 05 Jan 2021 | 2,400 | 277,723 (1%) | 0% | 7 | 16,800 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.00 per share. | 23 Dec 2020 | 4,800 | 280,123 (1%) | 0% | 7 | 33,600 | Common Stock |
| Arthur Taveras | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2020 | 121,150 | 121,150 | - | - | Stock Option (right to buy) | |
| Murray W. Stewart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Oct 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Alison F. Lawton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2020 | 6,854 | 6,854 | - | - | Stock Option (right to buy) | |
| Gary J. Bridger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2020 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.00 per share. | 05 Oct 2020 | 1,797 | 284,923 (1%) | 0% | 7 | 12,579 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.00 per share. | 02 Oct 2020 | 603 | 286,720 (1%) | 0% | 7 | 4,221 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.08 per share. | 21 Sep 2020 | 10,834 | 29,589 (0%) | 0% | 7.1 | 76,705 | Common Stock |
| Derek M. Meisner | General Counsel | Sale of securities on an exchange or to another person at price $ 8.05 per share. | 09 Sep 2020 | 8,334 | 16,666 (0%) | 0% | 8.1 | 67,089 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.04 per share. | 09 Sep 2020 | 8,840 | 287,323 (1%) | 0% | 8.0 | 71,074 | Common Stock |
| Renato Skerlj | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 8.05 per share. | 09 Sep 2020 | 5,834 | 42,076 (0%) | 0% | 8.1 | 46,964 | Common Stock |
| Paula S. Ragan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.99 per share. | 02 Sep 2020 | 2,400 | 296,163 (1%) | 0% | 8.0 | 19,176 | Common Stock |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2020 | 16,250 | 40,423 (0%) | 0% | 0 | Common Stock | |
| Adam S. Mostafa | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2020 | 16,250 | 24,173 (0%) | 0% | 0 | Common Stock | |
| Derek M. Meisner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2020 | 12,500 | 25,000 (0%) | 0% | 0 | Common Stock | |
| Derek M. Meisner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2020 | 12,500 | 12,500 (0%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2020 | 44,825 | 298,563 (1%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2020 | 44,826 | 253,738 (1%) | 0% | 0 | Common Stock | |
| Renato Skerlj | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2020 | 8,750 | 47,910 (0%) | 0% | 0 | Common Stock | |
| Renato Skerlj | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2020 | 8,750 | 39,160 (0%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | President and CEO | Sale of securities on an exchange or to another person at price $ 7.45 per share. | 03 Aug 2020 | 2,400 | 208,912 (1%) | 0% | 7.5 | 17,880 | Common Stock |
| Paula S. Ragan | President and CEO | Sale of securities on an exchange or to another person at price $ 9.05 per share. | 02 Jul 2020 | 2,400 | 211,312 (1%) | 0% | 9.1 | 21,720 | Common Stock |
| Adam S. Mostafa | See Remarks | Sale of securities on an exchange or to another person at price $ 9.04 per share. | 30 Jun 2020 | 1,725 | 8,839 (0%) | 0% | 9.0 | 15,594 | Common Stock |
| Adam S. Mostafa | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.32 per share. | 30 Jun 2020 | 916 | 7,923 (0%) | 0% | 9.3 | 8,537 | Common Stock |
| David W.J. McGirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 3,427 | 3,427 | - | - | Stock Option (right to buy) | |
| Michael Stephen Wyzga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 3,427 | 3,427 | - | - | Stock Option (right to buy) | |
| William E. Aliski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 3,427 | 3,427 | - | - | Stock Option (right to buy) | |
| Gary J. Bridger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 3,427 | 3,427 | - | - | Stock Option (right to buy) | |
| Rene Russo | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 3,427 | 3,427 | - | - | Stock Option (right to buy) | |
| Murray W. Stewart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 3,427 | 3,427 | - | - | Stock Option (right to buy) | |
| Renato Skerlj | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2020 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Paula S. Ragan | President and CEO | Sale of securities on an exchange or to another person at price $ 8.63 per share. | 01 Jun 2020 | 4,275 | 225,819 (1%) | 0% | 8.6 | 36,893 | Common Stock |
| Paula S. Ragan | President and CEO | Sale of securities on an exchange or to another person at price $ 8.88 per share. | 01 Jun 2020 | 9,707 | 213,712 (1%) | 0% | 8.9 | 86,198 | Common Stock |
| Paula S. Ragan | President and CEO | Sale of securities on an exchange or to another person at price $ 8.65 per share. | 01 Jun 2020 | 2,400 | 223,419 (1%) | 0% | 8.7 | 20,760 | Common Stock |
| Paula S. Ragan | President and CEO | Sale of securities on an exchange or to another person at price $ 8.92 per share. | 04 May 2020 | 2,400 | 230,094 (1%) | 0% | 8.9 | 21,408 | Common Stock |
| Paula S. Ragan | President and CEO | Sale of securities on an exchange or to another person at price $ 8.40 per share. | 02 Apr 2020 | 2,400 | 232,494 (1%) | 0% | 8.4 | 20,160 | Common Stock |
| Paula S. Ragan | President and CEO | Sale of securities on an exchange or to another person at price $ 10.64 per share. | 02 Mar 2020 | 2,400 | 234,894 (1%) | 0% | 10.6 | 25,536 | Common Stock |
| Derek M. Meisner | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2019 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| William E. Aliski | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2019 | 6,854 | 6,854 | - | - | Stock Option (right to buy) | |
| David W.J. McGirr | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 3,427 | 3,427 | - | - | Stock Option (right to buy) | |
| Rene Russo | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 3,427 | 3,427 | - | - | Stock Option (right to buy) | |
| Adam S. Mostafa | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 10,564 | 10,564 (0%) | 0% | 0 | Common Stock | |
| Adam S. Mostafa | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 15,847 | 15,847 | - | - | Stock Option (right to buy) | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 55,928 | 237,294 (1%) | 0% | 0 | Common Stock | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2019 | 83,893 | 83,893 | - | - | Stock Option (right to buy) | |
| Lynne Kelley | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Apr 2019 | 37,170 | 37,170 | - | - | Stock Option (right to buy) | |
| Murray W. Stewart | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2019 | 6,854 | 6,854 | - | - | Stock Option (right to buy) | |
| Michael Stephen Wyzga | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 70,324 | 70,324 | - | - | Stock Option (right to buy) | |
| Michael Stephen Wyzga | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 6,854 | 6,854 | - | - | Stock Option (right to buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 6,854 | 6,854 | - | - | Stock Option (right to buy) | |
| Isaac Blech | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 70,796 | 70,796 | - | - | Stock Option (right to buy) | |
| Gary J. Bridger | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 6,854 | 6,854 | - | - | Stock Option (right to buy) | |
| Gary J. Bridger | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 21,570 | 21,570 | - | - | Stock Option (right to buy) | |
| Adam S. Mostafa | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 62,633 | 62,633 | - | - | Stock Option (right to buy) | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 100,729 | 100,729 | - | - | Stock Option (right to buy) | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 80,160 | 80,160 | - | - | Stock Option (right to buy) | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 65,430 | 65,430 | - | - | Stock Option (right to buy) | |
| Paula S. Ragan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2019 | 181,366 | 181,366 (1%) | 2% | - | Common Stock | |
| Michael Gray | Director, President, CEO and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2018 | 250,000 | 250,000 (1%) | 1% | 0 | Common Stock | |
| Carl L Gordon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| David W.J. McGirr | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Terrance G. Mcguire | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Amy W. Schulman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| William D. Clark | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Michael Ross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Tillman U. Gerngross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Claudio Nessi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2018 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Michael Gray | COO and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 110,000 | 110,000 | - | - | Stock option (right to buy) | |
| David Mantus | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| Eszter Nagy | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 45,000 | 45,000 | - | - | Stock option (right to buy) | |
| Rene Russo | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 160,000 | 160,000 | - | - | Stock option (right to buy) | |
| Chris Stevens | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2018 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 653,974 | 1,368,966 (9%) | 4% | 0 | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 114,320 | 714,992 (5%) | 0% | 0 | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 328,909 | 600,672 (4%) | 2% | 0 | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 252,230 | 271,763 (1%) | 1% | 0 | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 19,533 | 19,533 (0%) | 0% | 0 | Common Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 66,667 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 704,846 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 2,232,014 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 500,000 | 1,868,966 (13%) | 3% | 10 | 5,000,000 | Common Stock |
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 736,648 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Carl L Gordon | Director, Ten Percent Owner | 20 Nov 2017 | 229,412 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 3,173 | 5,794 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 2,173 | 3,969 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 6,185 | 11,295 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 317,376 | 579,609 (4%) | 2% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 2,433 | 2,621 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 1,667 | 1,796 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 4,743 | 5,110 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 243,385 | 262,233 (1%) | 1% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 188 | 188 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 129 | 129 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 367 | 367 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 18,848 | 18,848 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 643 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 4,825 | 18,031 (0%) | 0% | 10 | 48,250 | Common Stock |
| Terrance G. Mcguire | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 3,305 | 12,351 (0%) | 0% | 10 | 33,050 | Common Stock |
| Terrance G. Mcguire | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 9,403 | 35,146 (0%) | 0% | 10 | 94,030 | Common Stock |
| Terrance G. Mcguire | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 482,467 | 1,803,429 (13%) | 3% | 10 | 4,824,670 | Common Stock |
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 6,310 | 13,206 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 4,322 | 9,046 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 12,298 | 25,743 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 631,041 | 1,320,962 (9%) | 4% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 1,102 | 6,896 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 755 | 4,724 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 2,150 | 13,445 (0%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 110,312 | 689,921 (5%) | 0% | 0 | Common Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 64,329 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 1,254 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 441 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 680,130 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 21,537 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 14,752 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 41,976 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 2,153,746 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 2,213 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 1,516 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 4,315 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 221,638 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 7,108 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 4,869 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 13,854 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 710,817 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 6,801 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 4,659 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Terrance G. Mcguire | Director, Ten Percent Owner | 20 Nov 2017 | 13,256 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 65,287 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 1,380 | 0 | - | - | Series A-1 Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 690,259 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 14,587 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 721,402 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 15,246 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 224,665 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 4,747 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 692,552 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 14,635 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 1,474,348 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 50,477 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 19,128 | 19,128 (0%) | 0% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 404 | 19,532 (0%) | 0% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 247,010 | 266,542 (1%) | 1% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 5,219 | 271,761 (1%) | 0% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 322,102 | 593,863 (4%) | 2% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 6,806 | 600,669 (4%) | 0% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 111,955 | 712,624 (5%) | 0% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 2,365 | 714,989 (5%) | 0% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 202,915 | 917,904 (6%) | 1% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 4,288 | 922,192 (6%) | 0% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 431,980 | 1,354,172 (9%) | 3% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | 20 Nov 2017 | 14,789 | 1,368,961 (9%) | 0% | 0 | Common Stock | ||
| Michael Ross | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 483,448 | 1,852,409 (13%) | 3% | 10 | 4,834,480 | Common Stock |
| Michael Ross | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 16,552 | 1,868,961 (13%) | 0% | 10 | 165,520 | Common Stock |
| Tillman U. Gerngross | None | 20 Nov 2017 | 90,272 | 192,821 (1%) | 0% | 0 | Common Stock | ||
| Tillman U. Gerngross | None | 20 Nov 2017 | 308,099 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Tillman U. Gerngross | None | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 200,000 | 392,821 (2%) | 1% | 10 | 2,000,000 | Common Stock |
| Claudio Nessi | None | Purchase of securities on an exchange or from another person at price $ 10.00 per share. | 20 Nov 2017 | 300,000 | 867,639 (6%) | 2% | 10 | 3,000,000 | Common Stock |
| Claudio Nessi | None | 20 Nov 2017 | 246,682 | 246,682 (1%) | 1% | 0 | Common Stock | ||
| Claudio Nessi | None | 20 Nov 2017 | 41,878 | 288,560 (2%) | 0% | 0 | Common Stock | ||
| Claudio Nessi | None | 20 Nov 2017 | 552,487 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Claudio Nessi | None | 20 Nov 2017 | 84,040 | 0 | - | - | Series C Convertible Preferred Stock | ||
| Claudio Nessi | None | 20 Nov 2017 | 952,497 | 0 | - | - | Series D Convertible Preferred Stock | ||
| Claudio Nessi | None | 20 Nov 2017 | 279,079 | 567,639 (4%) | 2% | 0 | Common Stock | ||
| Carl L Gordon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2017 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| David W.J. McGirr | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2017 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Terrance G. Mcguire | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2017 | 25,000 | 25,000 | - | - | Common Stock (right to buy) | |
| Amy W. Schulman | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2017 | 25,000 | 25,000 | - | - | Common Stock (right to buy) | |
| William D. Clark | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2017 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Michael Ross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2017 | 25,000 | 25,000 | - | - | Common Stock (right to buy) | |
| Tillman U. Gerngross | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2017 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Claudio Nessi | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2017 | 25,000 | 25,000 | - | - | Common Stock (right to buy) |